查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1736417

全球丙型肝炎检测市场规模（按检测套组、方法、最终用户、区域范围和预测）

Global Hepatitis C Testing Market Size By Test Kits (Hepatitis C Antibody Test, Hepatitis C RNA Quantitative Test), By Technique (Immunoassays, Polymerase Chain Reaction), By End-User (Hospitals, Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

丙型肝炎检测市场规模及预测

预计 2024 年丙型肝炎检测市场规模将达到 14.8 亿美元，到 2032 年将达到 25.1 亿美元，2026 年至 2032 年的复合年增长率为 7.50%。

  • 丙型肝炎检测是控制C型肝炎病毒(HCV) 感染的关键环节。 HCV 是一种血源性病毒，如果不及时治疗，可能导致严重的肝损伤。
  • 丙型肝炎病毒感染可透过抗病毒药物治癒。有效的治疗可以治癒丙型肝炎，并阻止肝病进展。
  • 早期诊断和治疗对于预防肝硬化和肝癌等併发症至关重要。
  • 根据美国疾病管制与预防中心 (CDC) 的数据，近三分之一的C型肝炎患者不知道自己的感染状况。
  • 美国疾病管制与预防中心建议对所有 18 岁或以上的成年人以及所有孕妇进行普遍丙型肝炎筛检。
  • 疾病预防控制中心建议对某些高风险族群进行更频繁的检测。

全球丙型肝炎检测市场动态

影响全球C型肝炎检测市场的关键市场动态是：

关键市场驱动因素

  • 丙型肝炎盛行率不断上升：C型肝炎病毒(HCV) 感染的日益普及推动了检测需求。根据世界卫生组织 (WHO) 估计，到 2023 年，预计将有 5,800 万人感染疾病慢性丙型肝炎病毒 (HCV)。如此高的盛行率凸显了广泛检测和早期诊断的迫切需求。
  • 扩大宣传和筛检项目宣传活动和不断扩展的筛检项目正在推动丙型肝炎检测市场的成长。美国疾病管制与预防中心报告称，2020年至2023年间，C型肝炎病毒检测率将增加32%。这些努力对于识别未确诊病例并预防进一步感染至关重要。
  • 就地检验趋势：快速就地检验正成为C型肝炎检测领域的主流。美国食品药物管理局)已于 2023 年核准三种新的C型肝炎就地检验，这表明这种方法的重要性日益提升。这些检测有助于更快速地诊断和启动治疗。
  • 诊断技术的进步：技术进步正在推动丙型肝炎检测的创新。根据美国国家卫生实验室的数据，包括C型肝炎病毒检测在内的全球分子诊断市场规模预计到2026年将达到318亿美元。这些创新正在提高检测的准确性和效率。

主要问题

  • 认识不足和耻辱感阻碍了检测率：许多有 HCV 感染风险的人可能没有意识到症状或检测的重要性，而围绕 HCV 感染的耻辱感可能会阻止人们接受检测或治疗。
  • 缺乏检测设施阻碍了早期诊断：检测设施有限会阻碍 HCV 感染的早期诊断，尤其是在服务不足的地区，这会导致治疗延迟和併发症风险增加。
  • 获得检测和治疗的成本障碍：HCV 检测和治疗的成本对于许多人来说是一个重大障碍，特别是那些低收入者，这可能会限制获得治疗的机会并阻碍早期诊断和治疗。
  • 复杂的监管环境阻碍市场扩张：了解丙型肝炎病毒（HCV）检测和治疗的监管环境非常复杂，尤其对于在多个地区运营的医疗保健提供者和製造商。遵守监管要求会增加成本，并阻碍市场扩张。

主要趋势

  • 加大对丙型肝炎消除工作的重视：全球消除丙型肝炎的努力正在推动检测倡议的扩展。世界卫生组织 (WHO) 报告称，截至 2023 年，21 个国家预计在 2030 年前实现丙型肝炎病毒消除。这些消除计划正在推动大规模检测的需求。
  • 丙型肝炎病毒检测在基层医疗中的整合度不断提升：丙型肝炎病毒检测在基层医疗体系中的整合度正在快速推进。欧洲疾病预防控制中心报告称，2021年至2023年间，基层医疗机构的C型肝炎病毒检测数量将增加45%。这一趋势正在改善检测和早期诊断的可及性。
  • 推动政府措施和资金筹措：不断增加的政府措施和资金投入正在推动丙型肝炎检测市场的发展。美国卫生与公众服务部已在2024财年拨款3.9亿美元用于病毒性肝炎的预防与治疗，较2023年增加15%。这些投资对于扩大检测项目至关重要。
  • 多重检测平台的采用日益增加：多重检测平台正日益普及，用于同时检测多种肝炎病毒。根据美国国家生物技术资讯中心的数据，2023年全球多重诊断市场（包括肝炎检测）的价值为39亿美元。这种方法提供了一种经济高效的检测解决方案。

目录

第 1 章全球丙型肝炎检测市场简介

  • 市场介绍
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球丙型肝炎检测市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球C型肝炎检测市场（依检测套组）

  • 概述
  • 丙型肝炎抗体检测
  • 丙型肝炎RNA定量检测
  • 丙型肝炎RNA定性检测
  • 肝炎 CRIBA
  • 丙型肝炎基因型
  • 病毒量

6. 全球C型肝炎检测市场（依最终用户）

  • 概述
  • 医院
  • 诊所
  • 诊断实验室
  • 其他的

7. 全球丙型肝炎检测市场（按技术）

  • 概述
  • 免疫检测
  • 聚合酵素链锁反应（PCR）
  • 其他的

8. 全球丙型肝炎检测市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 拉丁美洲
    • 中东和非洲

9. 全球C型肝炎检测市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Siemens Healthineers
  • Abbott Laboratories
  • Roche Diagnostics
  • Bio-Rad Laboratories
  • Thermo Fisher Scientific
  • Streck
  • Illumina Inc.
  • Merck KGaA
  • Qiagen

第十一章 重大进展

  • 产品发布/开发
  • 合併与收购
  • 业务扩展
  • 伙伴关係与合作

第十二章 附录

  • 相关调查
简介目录
Product Code: 36136

Hepatitis C Testing Market Size And Forecast

Hepatitis C Testing Market size was valued at USD 1.48 Billion in 2024 and is projected to reach USD 2.51 Billion by 2032, growing at a CAGR of 7.50% from 2026 to 2032.

  • Hepatitis C testing is a critical component of managing hepatitis C virus (HCV) infection. HCV is a blood-borne virus that can lead to severe liver damage if left untreated.
  • HCV infection is highly treatable with antiviral medications. Effective treatment can lead to a cure, preventing the progression of liver disease.
  • Early diagnosis and treatment are essential to prevent complications such as liver cirrhosis and liver cancer.
  • According to the Centers for Disease Control and Prevention (CDC), nearly one in three people with hepatitis C are unaware of their infection status.
  • CDC recommends universal hepatitis C screening for all adults 18 and older and all pregnant people during each pregnancy.
  • CDC recommends testing people in certain high-risk groups more frequently.

Global Hepatitis C Testing Market Dynamics

The key market dynamics that are shaping the global hepatitis C testing market include:

Key Market Drivers

  • Rising Prevalence of Hepatitis C: The increasing prevalence of Hepatitis C virus (HCV) infection is propelling the demand for testing. According to the World Health Organization, an estimated 58 million people were living with chronic HCV infection in 2023. This high prevalence underscores the urgent need for widespread testing and early diagnosis.
  • Growing Awareness and Screening Programs: Expanding awareness campaigns and screening programs are driving growth in the Hepatitis C testing market. The U.S. Centers for Disease Control and Prevention reported a 32% increase in HCV testing rates from 2020 to 2023. These initiatives are crucial for identifying undiagnosed cases and preventing further transmission.
  • Dominating Trend of Point-of-Care Testing: The shift towards rapid, point-of-care testing is dominating the Hepatitis C testing landscape. The U.S. Food and Drug Administration approved three new HCV point-of-care tests in 2023, demonstrating the growing importance of this approach. These tests enable faster diagnosis and treatment initiation.
  • Propelling Advancements in Diagnostic Technologies: Technological advancements are propelling innovations in Hepatitis C testing methods. The global molecular diagnostics market, which includes HCV testing, is projected to reach $31.8 billion by 2026, according to the National Institutes of Health. These innovations are improving test accuracy and efficiency.

Key Challenges:

  • Limited Awareness and Stigma Hindering Testing Rates: Many individuals at risk for HCV infection may not be aware of the symptoms or the importance of testing. Also, the stigma associated with HCV infection can deter individuals from seeking testing and treatment.
  • Lack of Access to Testing Facilities Hampering Early Diagnosis: Limited availability of testing facilities, particularly in underserved areas, can hinder early diagnosis of HCV infection. This can lead to delayed treatment and increased risk of complications.
  • Cost Barriers Obstructing Access to Testing and Treatment: The cost of HCV testing and treatment can be a significant barrier for many individuals, particularly in low-income communities. This can limit access to care and prevent early diagnosis and treatment.
  • Complex Regulatory Landscape Challenging Market Expansion: Navigating the regulatory landscape for HCV testing and treatment can be complex, especially for healthcare providers and manufacturers operating in multiple jurisdictions. Compliance with regulatory requirements can increase costs and hinder market expansion.

Key Trends

  • Rising Focus on Hepatitis C Elimination Efforts: Global efforts to eliminate Hepatitis C are driving increased testing initiatives. The World Health Organization reported that 21 countries were on track to achieve HCV elimination by 2030, as of 2023. These elimination programs are boosting demand for large-scale testing.
  • Growing Integration of HCV Testing in Primary Care: The integration of Hepatitis C testing into primary care settings is growing rapidly. The European Centre for Disease Prevention and Control reported a 45% increase in HCV testing at primary care facilities from 2021 to 2023. This trend is improving access to testing and early diagnosis.
  • Propelling Government Initiatives and Funding: Government initiatives and increased funding are propelling the Hepatitis C testing market forward. The U.S. Department of Health and Human Services allocated $390 million for viral hepatitis prevention and treatment in fiscal year 2024, a 15% increase from 2023. These investments are crucial for expanding testing programs.
  • Rising Adoption of Multiplex Testing Platforms: The adoption of multiplex testing platforms for simultaneous detection of multiple hepatitis viruses is rising. The global multiplex diagnostics market, including hepatitis testing, was valued at $3.9 billion in 2023, according to the National Center for Biotechnology Information. This approach offers cost-effective and efficient testing solutions.

Global Hepatitis C Testing Market Regional Analysis

Here is a more detailed regional analysis of the global hepatitis C testing market:

North America

  • North America dominates the global hepatitis C testing market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem.
  • According to the National Institutes of Health (NIH), the U.S. invested $45.1 billion in biomedical research in fiscal year 2023, fueling innovation in the sector.
  • This substantial funding has led to significant advancements in areas such as gene therapy and personalized medicine.
  • For instance, in February 15, 2024, Moderna announced the expansion of its mRNA pipeline, including 15 new programs in rare diseases and oncology, further solidifying North America's leadership in hepatitis C testing.
  • The region's market dominance is also driven by a high prevalence of chronic diseases and a supportive regulatory environment.
  • The Centers for Disease Control and Prevention (CDC) reported that 6 in 10 adults in the U.S. have a chronic disease as of 2023, creating a strong demand for innovative biotechnology solutions.
  • This demand is met by cutting-edge research and development efforts from industry leaders.
  • For instance, on September 8, 2023, Pfizer received FDA approval for its gene therapy treatment for hemophilia B, marking a significant milestone in hepatitis C testing applications and reinforcing North America's position at the forefront of the global market.

Asia Pacific

  • Asia Pacific is poised to emerge as the fastest-growing region in the global hepatitis C testing market during the forecast period, driven by the high prevalence, coupled with improving healthcare infrastructure and rising awareness, thus driving the market growth.
  • According to the World Health Organization's Western Pacific Region office, an estimated 39 million people were living with chronic hepatitis C in the region as of 2023, highlighting the urgent need for enhanced testing efforts.
  • On March 8, 2024, Abbott Laboratories announced the launch of its new rapid HCV test in India, aiming to increase access to quick and accurate diagnosis in resource-limited settings.
  • The region's growth is further fueled by government initiatives and increasing healthcare expenditure. China's National Health Commission reported a 40% increase in hepatitis C screening rates from 2021 to 2023, demonstrating a strong commitment to disease control.
  • also, the emerging economies are adopting advanced testing technologies to improve diagnostic accuracy and efficiency.
  • On November 15, 2023, Roche Diagnostics partnered with the Malaysian Ministry of Health to provide 1 million HCV tests as part of a nationwide elimination program, showcasing the collaborative efforts between industry leaders and governments to combat hepatitis C in the Asia Pacific region.

Global Hepatitis C Testing Market: Segmentation Analysis

The Global Hepatitis C Testing Market is segmented based on Test Kits, Technique, End-User, and Geography.

Hepatitis C Testing Market, By Test Kits

  • Hepatitis C Antibody Test
  • Hepatitis C RNA Quantitative Test
  • Hepatitis C RNA Qualitative Test
  • Hepatitis C RIBA
  • Hepatitis C Genotype
  • Viral Load

Based on Test Kits, the Global Hepatitis C Testing Market is bifurcated into Hepatitis C Antibody Test, Hepatitis C RNA Quantitative Test, Hepatitis C RNA Qualitative Test, Hepatitis C RIBA, Hepatitis C Genotype, Viral Load. The hepatitis C RNA quantitative test segment is currently dominating the global hepatitis C testing market, driven by its ability to accurately measure the viral load of HCV infection. However, the hepatitis C genotype test segment is experiencing rapid growth, as understanding the HCV genotype is essential for selecting the most effective treatment regimen.

Hepatitis C Testing Market, By Technique

  • Immunoassays
  • Polymerase Chain Reaction (PCR)
  • Others

Based on Technique, the Global Hepatitis C Testing Market is bifurcated into Immunoassays, Polymerase Chain Reaction (PCR), Others. The immunoassay segment is currently dominating the global hepatitis C testing market, owing to its established reputation for simplicity, affordability, and high sensitivity in detecting hepatitis C antibodies. However, polymerase chain reaction (PCR) segment is experiencing rapid growth, driven by its superior accuracy and ability to directly detect the hepatitis C virus, making it a valuable tool for early diagnosis and treatment monitoring.

Hepatitis C Testing Market, By End-User

  • Hospitals
  • Clinics
  • Diagnostic Laboratories
  • Others

Based on End-User, the Global Hepatitis C Testing Market is bifurcated into Hospital and Clinics, Diagnostic Laboratories, Others. The hospitals segment is currently dominating the global hepatitis C testing market, driven by the high volume of patients seeking testing and treatment in these facilities. However, the diagnostic laboratories segment is experiencing rapid growth, as healthcare providers increasingly rely on specialized laboratories for accurate and efficient testing services.

Hepatitis C Testing Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world

Based on Geography, the Global Hepatitis C Testing Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. North America dominates the global hepatitis C testing market, accounting for the largest share due to its advanced healthcare infrastructure and robust research ecosystem. However, Asia Pacific is poised to emerge as the fastest-growing region in the global hepatitis C testing market during the forecast period, driven by the high prevalence, coupled with improving healthcare infrastructure and rising awareness thus driving the market growth.

Key Players

The "Global Hepatitis C Testing Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott (U.S.), Bio-Rad Laboratories Inc., QIAGEN, Bayer AG, OraSure Technologies, Inc., Sysmex Corporation, Meridian Bioscience, Biogate Laboratories Ltd.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Hepatitis C Testing Market Key Developments

  • In February 2023, the Pune-based company Mylab Discovery Solutions declared that it would be launching three new rapid tests to identify STIs in a timely manner. STIs are a serious problem since, according to WHO estimates, there will be one million STI cases worldwide each day.
  • In September 2022, An IVD company called J Mitra unveiled the HCV Gen 4 Ag & Ab Microlisa, a fourth-generation Elisa-based HCV test. The purpose of the kit is to screen blood donors in order to identify and eliminate blood units that are contaminated. Hepatitis C can also be clinically diagnosed with this kit.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEPATITIS C TESTING MARKET

  • 1.1 Introduction of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEPATITIS C TESTING MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEPATITIS C TESTING MARKET, BY TEST KITS

  • 5.1 Overview
  • 5.2 Hepatitis C Antibody Test
  • 5.3 Hepatitis C RNA Quantitative Test
  • 5.4 Hepatitis C RNA Qualitative Test
  • 5.5 Hepatitis C RIBA
  • 5.6 Hepatitis C Genotype
  • 5.7 Viral Load

6 GLOBAL HEPATITIS C TESTING MARKET, BY END-USERS

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Clinics
  • 6.4 Diagnostic Laboratories
  • 6.5 Others

7 GLOBAL HEPATITIS C TESTING MARKET, BY TECHNOLOGY

  • 7.1 Overview
  • 7.2 Immunoassays
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Others

8 GLOBAL HEPATITIS C TESTING MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL HEPATITIS C TESTING MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Siemens Healthineers
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Abbott Laboratories
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Roche Diagnostics
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Bio-Rad Laboratories
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Thermo Fisher Scientific
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Streck
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Illumina Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Merck KGaA
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Qiagen
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments

11 KEY DEVELOPMENTS

  • 11.1 Product Launches/Developments
  • 11.2 Mergers and Acquisitions
  • 11.3 Business Expansions
  • 11.4 Partnerships and Collaborations

12 Appendix

  • 12.1 Related Research